PurposeIn this study, we aimed to use advanced machine learning (ML) techniques, specifically transfer learning and Vision Transformers (ViTs), to accurately classify meningioma in brain MRI scans. ViTs process images similarly to how humans visually perceive details and are useful for analyzing complex medical images. Transfer learning is a technique that uses models previously trained on large datasets and adapts them to specific use cases. Using transfer learning, this study aimed to enhance the diagnostic accuracy of meningioma location and demonstrate the capabilities the new technology. ApproachWe used a Google ViT model pre-trained on ImageNet-21k (a dataset with 14 million images and 21,843 classes) and fine-tuned on ImageNet 2012 (a dataset with 1 million images and 1,000 classes). Using this model, which was pre-trained and fine-tuned on large datasets of images, allowed us to leverage the predictive capabilities of the model trained on those large datasets without needing to train an entirely new model specific to only meningioma MRI scans. Transfer learning was used to adapt the pre-trained ViT to our specific use case, being meningioma location classification, using a dataset of 1,094 images of T1, contrast-enhanced, and T2-weighted MRI scans of meningiomas sorted according to location in the brain, with 11 different classes. ResultsThe final model trained and adapted on the meningioma MRI dataset achieved an average validation accuracy of 98.17% and a test accuracy of 89.95%. ConclusionsThis study demonstrates the potential of ViTs in meningioma location classification, leveraging their ability to analyze spatial relationships in medical images. While transfer learning enabled effective adaptation with limited data, class imbalance affected classification performance. Future work should focus on expanding datasets and incorporating ensemble learning to improve diagnostic reliability.

BackgroundAccurate prognostication of mobility outcomes is essential to guide rehabilitation and manage patient expectations. The prognostic utility of neuroimaging and neurophysiological biomarkers remains uncertain when measured early post-stroke. This systematic review aimed to examine the prognostic capacity of early neuroimaging and neurophysiological biomarkers of mobility outcomes up to 24-months post-stroke. MethodsMEDLINE and EMBASE were searched from inception to June 2025. Cohort studies that reported neuroimaging or neurophysiological biomarkers measured [≤]14-days post-stroke and mobility outcome(s) assessed >14-days and [≤]24-months post-stroke were included. Biomarker analyses were classified by statistical analysis approach (association, discrimination/classification or validation). Magnitude of relevant statistical measures was used as the primary indicator of prognostic capacity. Risk of bias was assessed using the Quality in Prognostic Studies tool. Meta-analysis was not performed due to heterogeneity. ResultsTwenty reports from 18 independent study samples (n=2,160 participants) were included. Biomarkers were measured a median 7.5-days post-stroke, and outcomes were assessed between 1- and 12-months. Eighty-six biomarker analyses were identified (61 neuroimaging, 25 neurophysiological) and the majority used an association approach (88%). Few used discrimination/classification methods (11%), and only one conducted internal validation (1%); an MRI-based machine learning model which demonstrated excellent discrimination but still requires external validation. Structural and functional corticospinal tract integrity were frequently investigated, and most associations were small or non-significant. Lesion location and size were also commonly examined, but findings were inconsistent and often lacked magnitude reporting. Methodological limitations were common, including small sample sizes, moderate to high risk of bias, poor reporting of magnitudes, and heterogeneous outcome measures and follow-up time points. ConclusionsCurrent evidence provides limited support for early neuroimaging and neurophysiological biomarkers to prognosticate post-stroke mobility outcomes. Most analyses remain at the association stage, with minimal progress toward validation and clinical implementation. Advancing the field requires international collaboration using harmonized methodologies, standardised statistical reporting, and consistent outcome measures and timepoints. RegistrationURL: https://www.crd.york.ac.uk/prospero/; Unique identifier: CRD42022350771.

Brain metastases represent one of the most common intracranial malignancies, yet early and accurate detection remains challenging, particularly in clinical datasets with limited availability of healthy controls. In this study, we developed a feature-based machine learning framework to classify patients with and without brain metastases using multi-modal clinical MRI scans. A dataset of 50 subjects from the UCSF Brain Metastases collection was analyzed, including pre- and post-contrast T1-weighted images and corresponding segmentation masks. We designed advanced feature extraction strategies capturing intensity, enhancement patterns, texture gradients, and histogram-based metrics, resulting in 44 quantitative descriptors per subject. To address the severe class imbalance (46 metastasis vs. 4 non-metastasis cases), we applied minority oversampling and noise-based augmentation, combined with stratified cross-validation. Among multiple classifiers, Random Forest consistently achieved the highest performance with an average accuracy of 96.7% and an area under the ROC curve (AUC) of 0.99 across five folds. The proposed approach highlights the potential of handcrafted radiomic-like features coupled with machine learning to improve metastasis detection in heterogeneous clinical MRI cohorts. These findings underscore the importance of methodological strategies for handling imbalanced data and support the integration of feature-based models as complementary tools for brain metastasis screening and research.

Obesity is a global public health priority and a major risk factor for cardiovascular disease (CVD). Emerging evidence indicates variation in pathologic consequences of obesity deposition across different body compartments. Biological heart age may be estimated from imaging measures of cardiac structure and function and captures risk beyond traditional measures. Using cardiac and abdominal magnetic resonance imaging (MRI) from 34,496 UK Biobank participants and linked health record data, we investigated how compartment-specific obesity phenotypes relate to cardiac ageing and incident CVD risk. Biological heart age was estimated using machine learning from 56 cardiac MRI phenotypes. K-means clustering of abdominal visceral (VAT), abdominal subcutaneous (ASAT), and pericardial (PAT) adiposity identified a high-risk cluster (characterised by greater adiposity across all three depots) associated with accelerated cardiac ageing - and a lower-risk cluster linked to decelerated ageing. These clusters provided more precise stratification of cardiovascular ageing trajectories than established body mass index categories. Mediation analysis showed that VAT and PAT explained 13.7% and 11.9% of obesity-associated CVD risk, respectively, whereas ASAT contributed minimally, with effects more pronounced in males. Thus, cardiovascular risk appears to be driven primarily by visceral and pericardial rather than subcutaneous fat. Our findings reveal a distinct risk profile of compartment-specific fat distributions and show the importance of pericardial and visceral fat as drivers of greater cardiovascular ageing. Advanced image-defined adiposity profiling may enhance CVD risk prediction beyond anthropometric measures and enhance mechanistic understanding.

Introduction Heart failure (HF) is a life-threatening syndrome with significant morbidity and mortality. While evidence-based drug treatments have effectively reduced morbidity and mortality in HF with reduced ejection fraction (HFrEF), few therapies have been demonstrated to improve outcomes in HF with preserved ejection fraction (HFpEF). The multifaceted clinical presentation is one of the main reasons why the current understanding of HFpEF remains limited. This may be caused by the existence of several HFpEF disease subtypes that each need different treatments. There is therefore an unmet need for a holistic approach that combines comprehensive imaging with metabolomic, transcriptomic and genomic mapping to subtype HFpEF patients. This protocol details the approach employed in the HeartMagic study to address this gap in understanding. Methods This prospective multi-center observational cohort study will include 500 consecutive patients with actual or recent hospitalization for treatment of HFpEF at two Swiss university hospitals, along with 50 age-matched HFrEF patients and 50 age-matched healthy controls. Diagnosis of heart failure is based on clinical signs and symptoms and subgrouping HF patients is based on the left-ventricular ejection fraction. In addition to routine clinical workup, participants undergo genomic, transcriptomic, and metabolomic analyses, while the anatomy, composition, and function of the heart are quantified by comprehensive echocardiography and magnetic resonance imaging (MRI). Quantitative MRI is also applied to characterize the kidney. The primary outcome is a composite of one-year cardiovascular mortality or rehospitalization. Machine learning (ML) based multi-modal clustering will be employed to identify distinct HFpEF subtypes in the holistic data. The clinical importance of these subtypes shall be evaluated based on their association with the primary outcome. Statistical analysis will include group comparisons across modalities, survival analysis for the primary outcome, and integrative multi-modal clustering combining clinical, imaging, ECG, genomic, transcriptomic, and metabolomic data to identify and validate HFpEF subtypes. Discussion The integration of comprehensive MRI with extensive genomic and metabolomic profiling in this study will result in an unprecedented panoramic view of HFpEF and should enable us to distinguish functional subgroups of HFpEF patients. This approach has the potential to provide unprecedented insights on HFpEF disease and should provide a basis for personalized therapies. Beyond this, identifying HFpEF subtypes with specific molecular and structural characteristics could lead to new targeted pharmacological interventions, with the potential to improve patient outcomes.

BackgroundBrain atrophy is a hallmark of multiple sclerosis (MS). For clinical translatability and individual-level predictions, brain atrophy needs to be put into context of the broader population, using reference or normative models. MethodsReference models of MRI-derived brain volumes were established from a large healthy control (HC) multi-cohort dataset (N=63 115, 51% females). The reference models were applied to two independent MS cohorts (N=362, T1w-scans=953, follow-up time up to 12 years) to assess deviations from the reference, defined as Z-values. We assessed the overlap of deviation profiles and their stability over time using individual-level transitions towards or out of significant reference deviation states (|Z|>1{middle dot}96). A negative binomial model was used for case-control comparisons of the number of extreme deviations. Linear models were used to assess differences in Z-score deviations between MS and propensity-matched HCs, and associations with clinical scores at baseline and over time. The utilized normative BrainReference models, scripts and usage instructions are freely available. FindingsWe identified a temporally stable, brain morphometric phenotype of MS. The right and left thalami most consistently showed significantly lower-than-reference volumes in MS (25% and 26% overlap across the sample). The number of such extreme smaller-than-reference values was 2{middle dot}70 in MS compared to HC (4{middle dot}51 versus 1{middle dot}67). Additional deviations indicated stronger disability (Expanded Disability Status Scale: {beta}=0{middle dot}22, 95% CI 0{middle dot}12 to 0{middle dot}32), Paced Auditory Serial Addition Test score ({beta}=-0{middle dot}27, 95% CI -0{middle dot}52 to -0{middle dot}02), and Fatigue Severity Score ({beta}=0{middle dot}29, 95% CI 0{middle dot}05 to 0{middle dot}53) at baseline, and over time with EDSS ({beta}=0{middle dot}07, 95% CI 0{middle dot}02 to 0{middle dot}13). We additionally provide detailed maps of reference-deviations and their associations with clinical assessments. InterpretationWe present a heterogenous brain phenotype of MS which is associated with clinical manifestations, and particularly implicating the thalamus. The findings offer potential to aid diagnosis and prognosis of MS. FundingNorwegian MS-union, Research Council of Norway (#223273; #324252); the South-Eastern Norway Regional Health Authority (#2022080); and the European Unions Horizon2020 Research and Innovation Programme (#847776, #802998). Research in contextO_ST_ABSEvidence before this studyC_ST_ABSReference values and normative models have yet to be widely applied to neuroimaging assessments of neurological disorders such as multiple sclerosis (MS). We conducted a literature search in PubMed and Embase (Jan 1, 2000-September 12, 2025) using the terms "MRI" AND "multiple sclerosis", with and without the keywords "normative model*" and "atrophy", without language restrictions. While normative models have been applied in psychiatric and developmental disorders, few studies have addressed their use in neurological conditions. Existing MS research has largely focused on global atrophy and has not provided regional reference charts or established links to clinical and cognitive outcomes. Added value of this studyWe provide regionally detailed brain morphometry maps derived from a heterogeneous MS cohort spanning wide ranges of age, sex, clinical phenotype, disease duration, disability, and scanner characteristics. By leveraging normative modelling, our approach enables individualised brain phenotyping of MS in relation to a population based normative sample. The analyses reveal clinically meaningful and spatially consistent patterns of smaller brain volumes, particularly in the thalamus and frontal cortical regions, which are linked to disability, cognitive impairment, and fatigue. Robustness across scanners, centres, and longitudinal follow-up supports the stability and generalisability of these findings to real-world MS populations. Implications of all the available evidenceNormative modelling offers an individualised, sensitive, and interpretable approach to quantifying brain structure in MS by providing individual-specific reference values, supporting earlier detection of neurodegeneration and improved patient stratification. A consistent pattern of thalamic and fronto-parietal deviations defines a distinct morphometric profile of MS, with potential utility for early and personalised diagnosis and disease monitoring in clinical practice and clinical trials.

We propose a deep learning approach for detecting anterior cruciate ligament (ACL) tears from knee MRI using a dual-branch convolutional architecture. The model independently processes sagittal and coronal MRI sequences using EfficientNet-B2 backbones with spatial attention modules, followed by a late fusion classifier for binary prediction. MRI volumes are standardized to a fixed number of slices, and domain-specific normalization and data augmentation are applied to enhance model robustness. Trained on a stratified 80/20 split of the MRNet dataset, our best model--using the Adam optimizer and a learning rate of 1e-4--achieved a validation AUC of 0.98 and a test AUC of 0.93. These results show strong predictive performance while maintaining computational efficiency. This work demonstrates that accurate diagnosis is achievable using only two anatomical planes and sets the stage for further improvements through architectural enhancements and broader data integration.

Automated thalamic nuclear segmentation has contributed towards a shift in neuroimaging analyses from treating the thalamus as a homogeneous, passive relay, to a set of individual nuclei, embedded within distinct brain-wide circuits. However, many studies continue to widely rely on FreeSurfers segmentation of T1-weighted structural MRIs, despite their poor intrathalamic nuclear contrast. Meanwhile, a convolutional neural network tool has been developed for FreeSurfer, using information from both diffusion and T1-weighted MRIs. Another popular thalamic nuclear segmentation technique is HIPS-THOMAS, a multi-atlas-based method that leverages white-matter-like contrast synthesized from T1-weighted MRIs. However, rigorous comparisons amongst methods remain scant, and the thalamic atlases against which these methods have been assessed have their own limitations. These issues may compromise the quality of cross-species comparisons, structural and functional connectivity studies in health and disease, as well as the efficacy of neuromodulatory interventions targeting the thalamus. Here, we report, for the first time, comparisons amongst HIPS-THOMAS, the standard FreeSurfer segmentation, and its more recent development, against two thalamic atlases as silver-standard ground-truths. We used two cohorts of healthy adults, and one cohort of patients in the chronic phase of autoimmune limbic encephalitis. In healthy adults, HIPS-THOMAS surpassed, not only the standard FreeSurfer segmentation, but also its more recent, diffusion-based update. The improvements made with the latter relative to the former were limited to a few nuclei. Finally, the standard FreeSurfer method underperformed, relative to the other two, in distinguishing between patients and healthy controls based on the affected anteroventral and pulvinar nuclei. In light of the above findings, we provide recommendations on the use of automated segmentation methods of the human thalamus using structural brain imaging.

BackgroundEarly detection of autism spectrum disorder (ASD) improves outcomes, yet clinical assessment is time-intensive. Artificial intelligence (AI) may support screening in preschool children by analysing behavioural, neurophysiological, imaging, and biomarker data. AimTo synthesise studies that applied AI in ASD assessment and evaluate whether the underlying data and AI approaches can distinguish ASD characteristics in early childhood. MethodsA systematic search of 15 databases was conducted on 30 November 2024 using predefined terms. Inclusion criteria were empirical studies applying AI to ASD detection in children aged 0-7 years. Reporting followed PRISMA 2020. ResultsTwelve studies met criteria. Reported performance (AUC) ranged from 0.65 to 0.997. Modalities included behavioural (eye-tracking, home videos), motor (tablet/reaching), EEG, diffusion MRI, and blood/epigenetic biomarkers. The largest archival dataset (M-CHAT-R) achieved near-perfect AUC with neural networks. Common limitations were small samples, male-skewed cohorts, and limited external validation. ConclusionsAI can aid early ASD screening in infants and preschoolers, but larger and more diverse datasets, rigorous external validation, and multimodal integration are needed before clinical deployment.

BackgroundAutomated interpretation of resting-state fMRI (rs-fMRI) for epilepsy diagnosis remains a challenge. We developed a regularized transformer that models parcel-wise spatial patterns and long-range temporal dynamics to classify epilepsy and generate interpretable, network-level candidate biomarkers. MethodsInputs were Schaefer-200 parcel time series extracted after standardized preprocessing (fMRIPrep). The Regularized Transformer is an attention-based sequence model with learned positional encoding and multi-head self-attention, combined with fMRI-specific regularization (dropout, weight decay, gradient clipping) and augmentation to improve robustness on modest clinical cohorts. Training used stratified group 4-fold cross-validation on n=65 (30 epilepsy, 35 controls) with fMRI-specific augmentation (time-warping, adaptive noise, structured masking). We compared the transformer to seven baselines (MLP, 1D-CNN, LSTM, CNN-LSTM, GCN, GAT, Attention-Only). External validation used an independent set (10 UNC epilepsy cohort, 10 controls). Biomarker discovery combined gradient-based attributions with parcelwise statistics and connectivity contrasts. ResultsOn an illustrative best-performing fold, the transformer attained Accuracy 0.77, Sensitivity 0.83, Specificity 0.88, F1-Score 0.77, and AUC 0.76. Averaged cross-validation performance was lower but consistent with these findings. External testing yielded Accuracy 0.60, AUC 0.64, Specificity 0.80, Sensitivity 0.40. Attribution-guided analysis identified distributed, network-level candidate biomarkers concentrated in limbic, somatomotor, default-mode and salience systems. ConclusionsA regularized transformer on parcel-level rs-fMRI can achieve strong within-fold discrimination and produce interpretable candidate biomarkers. Results are encouraging but preliminary larger multi-site validation, stability testing and multiple-comparison control are required prior to clinical translation.